{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:29:22Z","timestamp":1793316562258,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40268-024-00497-z","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T06:34:23Z","timestamp":1731652463000},"page":"539-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5111-867X","authenticated-orcid":false,"given":"Nishit B.","family":"Modi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Rudraraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Valone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"497_CR1","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1182\/blood.2022016779","volume":"141","author":"C Bennett","year":"2023","unstructured":"Bennett C, Jackson VE, Pettikiriarachchi A, Hayman T, Schaeper U, Moir-Meyer G, et al. Iron homeostasis governs erythroid phenotype in polycythemia vera. Blood. 2023;141:3199\u2013214. https:\/\/doi.org\/10.1182\/blood.2022016779.","journal-title":"Blood"},{"key":"497_CR2","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic J-P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144\u20138. https:\/\/doi.org\/10.1038\/nature03546.","journal-title":"Nature"},{"key":"497_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","volume":"17","author":"A Mullally","year":"2010","unstructured":"Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, et al. Physiological JAK2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17:584\u201396. https:\/\/doi.org\/10.1016\/j.ccr.2010.05.015.","journal-title":"Cancer Cell"},{"key":"497_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1208500.","journal-title":"N Engl J Med"},{"key":"497_CR5","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9:e301\u201311. https:\/\/doi.org\/10.1016\/S2352-3026(22)00046-1.","journal-title":"Lancet Haematol."},{"key":"497_CR6","unstructured":"NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) for myeloproliferative neoplasms V.1.2024.\u00a9 National Comprehensive Cancer Network, Inc. 2024. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1477. Accessed 12 Feb 2024."},{"key":"497_CR7","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1465\u201387. https:\/\/doi.org\/10.1002\/ajh.27002.","journal-title":"Am J Hematol"},{"key":"497_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00277-023-05089-6","volume":"102","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Pemmaraju N, Reaven NL, Funk SE, Woody T, et al. Real-world treatments and thrombotic events in polycythemia vera patients in the USA. Ann Hematol. 2023;102:571\u201381. https:\/\/doi.org\/10.1007\/s00277-023-05089-6.","journal-title":"Ann Hematol"},{"key":"497_CR9","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1152\/physrev.00008.2013","volume":"93","author":"T Ganz","year":"2013","unstructured":"Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93:1721\u201341. https:\/\/doi.org\/10.1152\/physrev.00008.2013.","journal-title":"Physiol Rev"},{"key":"497_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/blood-2013-06-427757","volume":"123","author":"D Meynard","year":"2014","unstructured":"Meynard D, Babitt JL, Lin HY. The liver: conductor of systemic iron balance. Blood. 2014;123:168\u201376. https:\/\/doi.org\/10.1182\/blood-2013-06-427757.","journal-title":"Blood"},{"key":"497_CR11","doi-asserted-by":"publisher","first-page":"7806","DOI":"10.1074\/jbc.M008922200","volume":"276","author":"CH Park","year":"2001","unstructured":"Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806\u201310. https:\/\/doi.org\/10.1074\/jbc.M008922200.","journal-title":"J Biol Chem"},{"key":"497_CR12","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1074\/jbc.M008923200","volume":"276","author":"C Pigeon","year":"2001","unstructured":"Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276:7811\u20139. https:\/\/doi.org\/10.1074\/jbc.M008923200.","journal-title":"J Biol Chem"},{"key":"497_CR13","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3945\/jn.108.096347","volume":"138","author":"JF Collins","year":"2008","unstructured":"Collins JF, Wessling-Resnick M, Knutson MD. Hepcidin regulation of iron transport. J Nutr. 2008;138:2284\u20138. https:\/\/doi.org\/10.3945\/jn.108.096347.","journal-title":"J Nutr"},{"key":"497_CR14","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1126\/science.1104742","volume":"306","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090\u20133. https:\/\/doi.org\/10.1126\/science.1104742.","journal-title":"Science"},{"key":"497_CR15","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3324\/haematol.2019.232124","volume":"105","author":"C Camaschella","year":"2020","unstructured":"Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105:260\u201372. https:\/\/doi.org\/10.3324\/haematol.2019.232124.","journal-title":"Haematologica"},{"key":"497_CR16","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1182\/blood-2011-01-258467","volume":"117","author":"T Ganz","year":"2011","unstructured":"Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117:4425\u201333. https:\/\/doi.org\/10.1182\/blood-2011-01-258467.","journal-title":"Blood"},{"key":"497_CR17","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood-2017-11-737411","volume":"131","author":"C Casu","year":"2018","unstructured":"Casu C, Nemeth E, Rivella S. Hepcidin agonists as therapeutic tools. Blood. 2018;131:1790\u20134. https:\/\/doi.org\/10.1182\/blood-2017-11-737411.","journal-title":"Blood"},{"key":"497_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.hoc.2013.11.004","volume":"28","author":"PJ Schmidt","year":"2014","unstructured":"Schmidt PJ, Fleming MD. Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches. Hematol Oncol Clin North Am. 2014;28:387\u2013401. https:\/\/doi.org\/10.1016\/j.hoc.2013.11.004.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Suppl. 1","key":"497_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/blood-2020-141720","volume":"136","author":"R Taranath","year":"2020","unstructured":"Taranath R, Bourne G, Zhang J, Frederick B, Tran TT, Bhandari A, et al. Hepcidin peptidomimetics: oral efficacy in pre-clinical disease model of iron overload. Blood. 2020;136(Suppl. 1):47\u20138.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"497_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2020-141670","volume":"136","author":"R Taranath","year":"2020","unstructured":"Taranath R, Mattheakis L, Zhao L, Lee L, Tovera J, Zhao J, et al. Mechanism of systemic iron regulation and hematocrit control by hepcidin peptidomimetics in pre-clinical models. Blood. 2020;136(Suppl. 1):49\u201350.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"497_CR21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1182\/blood-2021-149205","volume":"138","author":"Y Ginzburg","year":"2021","unstructured":"Ginzburg Y, Kirubamoorthy K, Salleh S, Lee S-E, Lee JH, Selvaratnam V, et al. Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy. Blood. 2021;138(Suppl. 1):390. https:\/\/doi.org\/10.1182\/blood-2021-149205.","journal-title":"Blood"},{"key":"497_CR22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa2308809","volume":"390","author":"M Kremyanskaya","year":"2024","unstructured":"Kremyanskaya M, Kuykendall AT, Pemmaraju N, Ritchie EK, Gotlib J, Gerds A, et al. Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera. N Engl J Med. 2024;390:723\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2308809.","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"497_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1182\/blood-2023-178253","volume":"142","author":"EK Ritchie","year":"2023","unstructured":"Ritchie EK, Pettit KM, Kuykendall AT, Kremyanskaya M, Pemmaraju N, Khanna S, et al. Durability of hematocrit control in polycythemia vera with the first-in-class hepcidin mimetic rusfertide: two-year follow up results from the Revive study. Blood. 2023;142(Suppl. 1):745.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"497_CR24","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1182\/blood-2022-163755","volume":"140","author":"S Verstovsek","year":"2022","unstructured":"Verstovsek S, Kuykendall A, Hoffman R, Koschmieder S, Passamonti F, Valone F, et al. Verify: a phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera. Blood. 2022;140(Suppl. 1):3929\u201331.","journal-title":"Blood"},{"key":"497_CR25","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S2468-1253(23)00250-9","volume":"8","author":"KV Kowdley","year":"2023","unstructured":"Kowdley KV, Modi NB, Peltekian K, Vierling JM, Ferris C, Valone FH, et al. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:1118\u201328. https:\/\/doi.org\/10.1016\/S2468-1253(23)00250-9.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"497_CR26","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/ejh.14243","volume":"113","author":"NB Modi","year":"2024","unstructured":"Modi NB, Shames R, Lickliter JD, Gupta S. Pharmacokinetics, pharmacodynamics and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: a double-blind first-in-human study. Eur J Haematol. 2024;113:340\u201350. https:\/\/doi.org\/10.1111\/ejh.14243.","journal-title":"Eur J Haematol"},{"key":"497_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1021\/bp070462h","volume":"24","author":"N Rathore","year":"2008","unstructured":"Rathore N, Rajan RS. Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog. 2008;24:504\u201314. https:\/\/doi.org\/10.1021\/bp070462h.","journal-title":"Biotechnol Prog"},{"key":"497_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.addr.2015.05.006","volume":"93","author":"MT Cicerone","year":"2015","unstructured":"Cicerone MT, Pikal MJ, Qian KK. Stabilization of proteins in solid form. Adv Drug Deliv Rev. 2015;93:14\u201324. https:\/\/doi.org\/10.1016\/j.addr.2015.05.006.","journal-title":"Adv Drug Deliv Rev"},{"key":"497_CR29","unstructured":"International Council for Harmonisation (ICH). U.S. Department of Health and Human Services. Food and Drug Administration. M10 bioanalytical method validation and study sample analysis. Guidance for industry. November 2022. Available from: https:\/\/www.fda.gov\/media\/162903\/download. Accessed 28 Jan 2024."},{"key":"497_CR30","unstructured":"National Cancer Institute Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program. Common terminology criteria for adverse events (CTCAE) v5.0. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 28 Jan 2024."},{"key":"497_CR31","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/009286159502900324","volume":"29","author":"K Gough","year":"1995","unstructured":"Gough K, Hutchinson M, Keene O, Byrom B, Ellis S, Lacey L, et al. Assessment of dose proportionality: report from statisticians in the pharmaceutical industry\/pharmacokinetics UK joint working party. Drug Inf J. 1995;29:1039\u201348. https:\/\/doi.org\/10.1177\/009286159502900324.","journal-title":"Drug Inf J"},{"key":"497_CR32","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1023\/a:1026451721686","volume":"17","author":"BP Smith","year":"2000","unstructured":"Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17:1278\u201383. https:\/\/doi.org\/10.1023\/a:1026451721686.","journal-title":"Pharm Res"},{"issue":"Suppl. 1","key":"497_CR33","doi-asserted-by":"publisher","first-page":"12241","DOI":"10.1182\/blood-2022-163847","volume":"140","author":"AT Gerds","year":"2022","unstructured":"Gerds AT, Gotlib J, Palmer JM, Pemmaraju N, Bose P, Ginzburg Y, et al. Rusfertide for polycythemia vera: similar dosing in patients receiving therapeutic phlebotomy alone or in combination with cytoreductive treatment. Blood. 2022;140(Suppl. 1):12241\u20133.","journal-title":"Blood"},{"key":"497_CR34","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1007\/s11095-012-0739-z","volume":"29","author":"I Jonassen","year":"2012","unstructured":"Jonassen I, Havelund S, Hoeg-Jensen T, Steengaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104\u201314. https:\/\/doi.org\/10.1007\/s11095-012-0739-z.","journal-title":"Pharm Res"},{"key":"497_CR35","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1007\/s11095-014-1614-x","volume":"32","author":"S Havelund","year":"2015","unstructured":"Havelund S, Ribel U, Hub\u00e1lek F, Hoeg-Jensen T, Wahlund PO, Jonassen I. Investigation of the physico-chemical properties that enable co-formulation of basal insulin degludec with fast-acting insulin aspart. Pharm Res. 2015;32:2250\u20138. https:\/\/doi.org\/10.1007\/s11095-014-1614-x.","journal-title":"Pharm Res"},{"key":"497_CR36","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1208\/s12248-011-9268-7","volume":"13","author":"C Avanti","year":"2011","unstructured":"Avanti C, Amorij J-P, Setyaningsih D, Hawe A, Jiskoot W, Visser J, et al. A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer. AAPS J. 2011;13:284\u201390. https:\/\/doi.org\/10.1208\/s12248-011-9268-7.","journal-title":"AAPS J"},{"key":"497_CR37","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1021\/mp200622z","volume":"9","author":"C Avanti","year":"2012","unstructured":"Avanti C, Permentier HP, van Dam A, Poole R, Jiskoot W, Frijlink HW, et al. A new strategy to stabilize oxytocin in aqueous solutions: II. Suppression of cysteine-mediated intermolecular reactions by a combination of divalent metal ions and citrate. Mol Pharm. 2012;9:554\u201362. https:\/\/doi.org\/10.1021\/mp200622z.","journal-title":"Mol Pharm"},{"key":"497_CR38","unstructured":"US Food and Drug Administration (FDA), Center for Drug Evaluation and Research. US Department of Health and Human Services. Guidance for industry: safety testing of drug metabolites, 2008. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/safety-testing-drug-metabolites. Accessed 28 Jan 2024."},{"key":"497_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","volume":"128","author":"C Casu","year":"2016","unstructured":"Casu C, Oikonomidou PR, Chen H, Nandi V, Ginzburg Y, Prasad P, et al. Minihepcidin peptides as disease modifiers in mice affected by \u03b2-thalassemia and polycythemia vera. Blood. 2016;128:265\u201376. https:\/\/doi.org\/10.1182\/blood-2015-10-676742.","journal-title":"Blood"},{"key":"497_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251995","volume":"16","author":"C Casu","year":"2021","unstructured":"Casu C, Liu A, De Rosa G, Low A, Suzuki A, Sinha S, et al. Tmprss6-ASO as a tool for the treatment of polycythemia vera mice. PLoS ONE. 2021;16: e0251995. https:\/\/doi.org\/10.1371\/journal.pone.0251995.","journal-title":"PLoS ONE"},{"key":"497_CR41","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1182\/blood.2023020509","volume":"41","author":"D Girelli","year":"2023","unstructured":"Girelli D, Busti F. Manipulating hepcidin in polycythemia vera. Blood. 2023;41:3132\u20134. https:\/\/doi.org\/10.1182\/blood.2023020509.","journal-title":"Blood"},{"key":"497_CR42","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s12325-022-02421-w","volume":"40","author":"T Ganz","year":"2023","unstructured":"Ganz T, Nemeth E, Rivella S, Goldberg P, Dibble AR, et al. TMPRSS6 as a therapeutic target for disorders of erythropoiesis and iron homeostasis. Adv Ther. 2023;40:1317\u201333. https:\/\/doi.org\/10.1007\/s12325-022-02421-w.","journal-title":"Adv Ther"},{"key":"497_CR43","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/ajh.27015","volume":"98","author":"JB Porter","year":"2023","unstructured":"Porter JB, Scrimgeour A, Martinez A, James L, Aleku M, Wilson R, et al. SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces iron and increases hepcidin levels of healthy volunteers. Am J Hematol. 2023;98:1425\u201335. https:\/\/doi.org\/10.1002\/ajh.27015.","journal-title":"Am J Hematol"},{"issue":"Suppl. 1","key":"497_CR44","doi-asserted-by":"publisher","first-page":"8178","DOI":"10.1182\/blood-2022-162702","volume":"140","author":"HE Lob","year":"2022","unstructured":"Lob HE, Ivanova L, Crowell B, Kim H, Idone V, Economides AN, et al. TMPRSS6 inhibition with a monoclonal antibody improves red blood cell health and reduces hepatic iron loading in mouse models of iron overload diseases. Blood. 2022;140(Suppl. 1):8178. https:\/\/doi.org\/10.1182\/blood-2022-162702.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"497_CR45","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1182\/blood-2023-174782","volume":"142","author":"B Chen","year":"2023","unstructured":"Chen B, Wang J, Huang L, Bujold M, Du X. Novel anti-TMPRSS6 monoclonal antibody provides a potential therapeutic approach for the treatment of polycythemia vera. Blood. 2023;142(Suppl. 1):3837. https:\/\/doi.org\/10.1182\/blood-2023-174782.","journal-title":"Blood"},{"key":"497_CR46","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1208\/s12248-010-9222-0","volume":"12","author":"JJ Xiao","year":"2010","unstructured":"Xiao JJ, Krzyzanski W, Wang Y-M, Li H, Rose MJ, Ma M, et al. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J. 2010;12:646\u201357. https:\/\/doi.org\/10.1208\/s12248-010-9222-0.","journal-title":"AAPS J"},{"key":"497_CR47","unstructured":"Yaeger D, Piga A, Lal A, Kattamis A, Salman S, Byrnes B, et al. A phase 1, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics of escalating subcutaneous doses of LJPC-401 (synthetic human hepcidin) in healthy subjects. Presented at the European Hematology Association 23rd Annual Congress; June 14\u201317, 2018; Stockholm."},{"key":"497_CR48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajh.25670","volume":"95","author":"F Richard","year":"2020","unstructured":"Richard F, van Lier JJ, Roubert B, Haboubi T, G\u00f6hring U-M, D\u00fcrrenberger F. Oral ferroportin inhibitor VIT-2763: first-in-human, phase 1 study in healthy volunteers. Am J Hematol. 2020;95:68\u201377. https:\/\/doi.org\/10.1002\/ajh.25670.","journal-title":"Am J Hematol"},{"key":"497_CR49","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","volume":"32","author":"YZ Ginzburg","year":"2018","unstructured":"Ginzburg YZ, Feola M, Zimran E, Varkonyi J, Ganz T, Hoffman R. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32:2105\u201316. https:\/\/doi.org\/10.1038\/s41375-018-0207-9.","journal-title":"Leukemia"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00497-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-024-00497-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00497-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T03:12:19Z","timestamp":1734491539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-024-00497-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["497"],"URL":"https:\/\/doi.org\/10.1007\/s40268-024-00497-z","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"31 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical trial was funded by Protagonist Therapeutics, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nishit B. Modi, Sarita Khanna, Sneha Rudraraju, and Frank Valone are current or previous employees or consultants of Protagonist Therapeutics, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The clinical trial was approved by an independent institutional review board (Advarra) and the trial was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the trial.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Anonymized individual patient data may be available upon request or as required by law or regulation with qualified external researchers and demonstrated non-conflict of interest. Approval of such requests is at the discretion of Protagonist Therapeutics, Inc. and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"NBM and FHV contributed with the conception and design of the trial, data collection and analyses, and critical manuscript revision; SR contributed to the data analysis; SK contributed to the data analysis, and critical manuscript revision. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}